In vitro modulation of interleukin-2-mediated human peripheral mononuclear cell proliferation and antitumor cytotoxicity by 5-fluorouracil

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 4135-4141

  Brazowski, Eli ^a   Eytan, Karin ^a   Eisenthal, Avi ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

5 fluorouracil; Activated NK cells; DNA synthesis; Human peripheral mononuclear cells; IL 2

Indexed keywords

FLUOROURACIL; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN;

ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; KINETICS; NATURAL KILLER CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL GROWTH PROCESSES; DNA; FLUOROURACIL; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PHYTOHEMAGGLUTININS; POKEWEED MITOGENS;

EID: 37549063892     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nozue M, Isaka N Maruyama T, Kawamoto T, Seino KI, Tanagichi H and Fukao K: Treatment of advanced colorectal adenocarcinoma with weekly high-dose 1-leucovorin and 5-fluorouracil. Oncol Rep 9: 93-106, 2002.
2. Porta C, Danova M, Accurso S, Tinelli C, Girino M, Riccardi A and Palmeri S: Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. Cancer Chemother Pharmacol 47: 423-428, 2001.
3. Aballea S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S and Bridgewater J: Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109: 1082-1089, 2007.
4. Sohn KJ, Croxford R, Yates Z, Lucock M and Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144, 2004.
5. Tong D, Poot M, Hu D and Oda D: 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncol 36: 236-241, 2000.
6. Leo S, Tatulli C, Taveri R, Campanella GA, Carrieri G and Colucci G: Dermatology toxicity from chemotherapy containing 5-fluorouracil. J Chemother 6: 423-426, 1994.
7. Nio Y, Imai S, Shiraishi T, Ohgaki K and Tobe T: Lymphocytes anticancer chemosensitivity testing in vitro- an approach to predict immunosuppressive effect of anticancer agents. J Clin Lab Immunol 29: 141-145, 1989.
8. Okamoto M, Kasetan H, Kaji R, Goda H, Ohe G, Yoshida H and Sato M: Cis-diaminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 47: 233-241, 1998.
9. Reiter Z, Ozes ON, Blatt LM and Taylor MW: A dual antitumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 62: 103-111, 1992.
10. Meurette O, Fontaine A, Rebillard A, Le-Moigne G, LamyT, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann NY Acad Sci 1090: 209-216, 2006.
11. De-Filippi R, Prete SP, Giuliani A, Silvi E, Yamaue H, Nieroda CA, Greiner JW, De-Vacchis L and Bonmassar E: Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells. Anticancer Res 14: 1767-1773, 1994.
12. Kobayashi R, Yoshimatsu K, Ishibashi K, Yokomizo H, Umehara A, Yoshida K, Fujimoto T, Watanabe K and Ogawa K: Host immunity in colorectal cancer patients treated with low-dose leucovorin plus 5-fluorouracil. Cancer Chemother 31: 1783-1785, 2004.
13. Clemenceau B, Gallot G, Vivien R, Gaschet J, Campone M and Vie H: Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J Immunother 29: 53-60, 2006.
14. Cartier A and Masucci MG: Differential regulation of MHC class-I-restricted and unrestricted cytotoxicity by the Us3 protein kinase of herpes simplex virus-1. Scand J Immunol 60: 592-599, 2004.
15. Hsiao YW, Liao KW, Hung SW and Chu RM: Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 172: 1508-1514, 2004.
16. Walker W and Rotondo D: Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 111: 298-305, 2004.
17. Eisenthal A, Barbarsteyn E, Gitstein G and Lifschitz-Mercer B: Inhibition of lymphokine-activated killer cells generation in-vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear (PBMC) adherent cells culture. Cancer Invest 24: 28-34, 2006.
18. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG, Bastounis EA and Papamichail M: Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 33: 1202-1208, 1997.
19. Shimizu H, Ito H, Kimura F, Togawa A, Yoshidome H, Ohtsuka M, Kato A, Nukui Y and Miyazaki M: Decreased cell-mediated immune status in colorectal cancer patients with hepatic metastasis. Hepatogastroenterology 52: 1106-1109, 2005.
20. Zhu Z, Fu Q, Nightingale CH, Zhao YP, Liao Q and Li DK: Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. Anticancer Drugs 9: 685-688, 1998.
21. Golab J, Zagozdson R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W and Jacobisiak M: Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15: 613-620, 2001.
22. Onocera H, Somers SS and Guillou PJ: Paradoxica effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer 62: 1042-1046, 1990.
23. Ehrnrooth E, Sorensen B, Poulsen JH, Sorensen BS and von der Maase H: Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. Acta Oncol 39: 53-57, 2000.
24. Arner ES and Eriksson S: Catabolism of deoxycytidine in human peripheral blood mononuclear cells and its interference with the determination of in situ thymidylate synthase activity. Anal Biochem 210: 102-105, 1993.
25. Daemen T, Regts J, Morselt H and Scherphof GL: The effect of liver macrophages on in vitro cytolytic activity of 5-FU and FudR on colon carcinoma cells. Int J Immunopharmacol 14: 857-864, 1994.
26. Billiau AD, Sefrioui H, Overbergh L, Rutgeerts O, Goebels J, Mathieu C and Waer M: Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras. Transplantation 71: 292-299, 2001.
27. Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N and Ben-Eliyahu S: Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 19: 114-126, 2005.
28. Fulton A, Miller F, Weise A and Wei WZ: Prospects of controlling breast cancer metastasis by immune intervention. Breast Dis 26: 115-27, 2006-2007.
29. Swisher SG, Economou JS, Holmes EC and Golub SH: TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function. Cell Immunol 128: 450-461, 1990.
30. Minami K, Yamaguchi Y, Yoshida K, Quan CP and Toge T: Dysregulation of telomerase activity and expression in lymphokine-activated killer cells from advanced cancer patients: possible involvement in cancer-associated immunosuppression mechanism. Oncol Rep 8: 649-653, 2001.
31. Eisenthal A: Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2. Cancer Immunol Immunother 31: 342-348, 1990.
32. Eisenthal A and Rosenberg SA: The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha. J Immunol 142: 2307-2313, 1989.